Akebia signs multi-year supply agreement with leading dialysis org for Vafseo access

Akebia Therapeutics, Inc.

Contract with a leading kidney care provider serving >200,000 patients at thousands of U.S. dialysis centers.
Vafseo (vadadustat) expected to be available in the U.S. in January 2025.
CMS granted TDAPA reimbursement for Vafseo starting January 1, 2025, and issued a HCPCS billing code.
Vafseo received FDA approval in March 2024 for anemia due to CKD in adults on dialysis for at least 3 months.
Agreement enables physicians to prescribe Vafseo as clinically appropriate; commercial launch priority.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.